Top Tips in Evidence-Based Care for HFrEF

Typical Patient With HFrEF

Key Therapies in HFrEF: How Do They Work?

2016 ESC HF Guidelines: Next...Add an MRA and ARNI

Principles for Successful Treatment for HF

Starting and Titrating Drug Therapies in HFrEF

ESC 2016 Guidelines: Classifications of HF

CHARM: Candesartan Reduced CV Death + Time to First HF Hospitalization in HFrEF and HFmrEF Categories

Benefit of ARNI in HFrEF: Primary Composite Endpoint -- CV Death and First HF Hospitalization

Additional Key Points: PARADIGM-HF

PARADIGM-HF: Benefit of ARNI in HFrEF to Reduce Time to First Hospitalization for HF Was Seen Very Early

Managing Diabetes in the Presence of HFrEF

SGLT2 Inhibitors: Use in Diabetes and HF

Ongoing Trials With SGLT2 Inhibitors in Patients With Diabetes and HF

Questions to Ponder and Points of Clarification: SGLT2 Inhibitors in HF

Altered Patient Scenario: Tachycardia in HFrEF

SHIFT Trial: Increased Risk of CV Death and HF Hospitalization With Increased Heart Rate in SR in HF

AF and HF

Heart Rate as a Predictor of Outcome in HF

Anticoagulation and AF in HF

Management of HF in the Inpatient Setting

PIONEER HF: Safety of ARNI -- Including ACE Inhibitor and ARB-Naive Patients With HFrEF

PIONEER HF: Exploratory Clinical Endpoints

Clarification of Terms -- What Do We Mean?

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)